Cardiac tumors screening
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors screening On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors screening |
|
Risk calculators and risk factors for Cardiac tumors screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Dj
Overview
Screening
- According to the USPSTF, routine screening for cardiac tumors is not recommended.
- Transthoracic echocardiography (TTE) continues to be the method of choice for screening for cardiac malignancies. Transesophageal echocardiogram (TEE) is commonly used for valvular lesions.[1]
- Emerging technologies such as contrast echocardiography and three-dimensional echocardiogram may substantially improve the diagnostic accuracy of echocardiography.[2]
- The diagnostic accuracy of echocardiography is 80%. After initial diagnosis on TTE, cardiac CT/MRI are commonly used to stage and further evaluate the tumors.[3]
- In patients undergoing myxoma resection, routine echocardiography screening must be performed one year following removal of myxoma and then every five years.[1]
- Pediatric patients with tuberous sclerosis require monitoring because of the risk of rhabdomyoma.
- At the initial diagnosis, electrocardiograms and echocardiography must be performed on all kids with tuberous sclerosis.
- Periodic monitoring of electrocardiograms are advised every three to five years due to the lifetime risk of arrhythmia regardless of the presence early-onset cardiac rhabdomyoma. [4]
References
- ↑ 1.0 1.1 Lamba G, Frishman WH (2012). "Cardiac and pericardial tumors". Cardiol Rev. 20 (5): 237–52. doi:10.1097/CRD.0b013e31825603e7. PMID 22447042.
- ↑ Mankad R, Herrmann J (2016). "Cardiac tumors: echo assessment". Echo Res Pract. 3 (4): R65–R77. doi:10.1530/ERP-16-0035. PMC 5292983. PMID 27600455.
- ↑ Nomoto N, Tani T, Konda T, Kim K, Kitai T, Ota M; et al. (2017). "Primary and metastatic cardiac tumors: echocardiographic diagnosis, treatment and prognosis in a 15-years single center study". J Cardiothorac Surg. 12 (1): 103. doi:10.1186/s13019-017-0672-7. PMC 5704631. PMID 29183343.
- ↑ Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK, International Tuberous Sclerosis Consensus Group (2014). "Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group". J Am Heart Assoc. 3 (6): e001493. doi:10.1161/JAHA.114.001493. PMC 4338742. PMID 25424575.